List view / Grid view
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
27 September 2013 | By Takeda Pharmaceutical Company Limited
TAK-816 is a Haemophilus Influenzae type b (Hib) vaccine...
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
26 September 2013 | By Penn Pharma
A £14 million state-of-the-art facility formally opened...
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
25 September 2013 | By GSK
European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection...
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
25 September 2013 | By AbbVie
Global alliance formed to discover, develop and commercialise novel potentiator and combination therapies in cystic fibrosis...
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
